A Study of DS5361b in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT07182591
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $108,950
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 192
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS5361b (drug), Pembrolizumab (drug)
- Dates
- Started 2025-10-02; completion 2030-12-03
- Results posted
- Not yet
This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.
From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $108,950 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Judy S. Wang, MD Medical Oncology · Sarasota, FL
- Shiraj Sen, M.D. Hematology & Oncology · Irving, TX
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Oncology-San Antonio $63,250
- Sarah Cannon Research Institute $45,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.